BioCryst Pharmaceuticals (BCRX) is Upgraded by Piper Jaffray to Overweight

BioCryst Pharmaceuticals (BCRX) was Upgraded by Piper Jaffray to ” Overweight”. Earlier the firm had a rating of “Neutral ” on the company shares. Piper Jaffray advised their investors in a research report released on Aug 12, 2016.

Many Wall Street Analysts have commented on BioCryst Pharmaceuticals. BioCryst Pharmaceuticals was Downgraded by JMP Securities to ” Mkt Perform” on Aug 4, 2016.

On the company’s financial health, BioCryst Pharmaceuticals reported $-0.22 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.26. The company had revenue of $4.80 million for the quarter, compared to analysts expectations of $4.33 million. The company’s revenue was down -81.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.06 EPS.

BioCryst Pharmaceuticals opened for trading at $4.21 and hit $4.224 on the upside on Monday, eventually ending the session at $4.19, with a gain of 1.21% or 0.05 points. The heightened volatility saw the trading volume jump to 7,20,278 shares. Company has a market cap of $309 M.

In a different news, on Aug 11, 2016, Thomas R Ii Staab (Senior Vice President and CFO) sold 14,577 shares at $4.43 per share price. According to the SEC, on Jun 22, 2015, William P Sheridan (Senior VP – CMO) sold 70,389 shares at $15.05 per share price. On Jun 22, 2015, Alane P Barnes (VP, General Counsel & Corp Sec) sold 3,000 shares at $15.00 per share price, according to the Form-4 filing with the securities and exchange commission.

BioCryst Pharmaceuticals Inc. (BioCryst) is a biotechnology company. The Company designs optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its products include RAPIVAB BCX4161 BCX7353 and other second generation HAE compounds BCX4430 and Forodesine. Peramivir is an intravenous neuraminidase inhibitor approved in multiple countries for the treatment of patients with influenza in the United States as RAPIVAB in Japan as RAPIACTA and in Korea as PERAMIFLU. BCX4161 is the Company’s Hereditary Angioedema (HAE) product candidate. BCX7353 is a plasma kallikrein inhibitor. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor.

BioCryst Pharmaceuticals

Leave a Reply

BioCryst Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on BioCryst Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.